openPR Logo
Press release

Chikungunya Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight

10-10-2025 03:04 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Chikungunya Pipeline Drugs Report 2025: Emerging Therapies,

DelveInsight's "Chikungunya Pipeline Insight 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Chikungunya pipeline landscape. It covers the Chikungunya Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chikungunya Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Chikungunya Pipeline? Click here to explore the therapies and trials making headlines @ Chikungunya Pipeline Outlook Report [https://www.delveinsight.com/sample-request/chikungunya-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chikungunya Pipeline Report

* In August 2025, Valneva Austria GmbH conducted a clinical trial will be to evaluate persistence of antibodies annually from 1 to 10 years after the single immunization with VLA1553. The secondary objective is to evaluate long-term safety 6 months to 2 years after the single immunization with VLA1553.
* DelveInsight's Chikungunya Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Chikungunya treatment.
* The leading Chikungunya Companies such as Najit Technologies, Inc., Auro Vaccines, Clayton Biotechnologies Inc . and others.
* Promising Chikungunya Pipeline Therapies such as MV-CHIK, MMR-vaccine, VLA1553, V184 , and others.

Want to know which companies are leading innovation in Chikungunya? Dive into the full pipeline insights @ Chikungunya Clinical Trials Assessment [https://www.delveinsight.com/sample-request/chikungunya-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Chikungunya Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Chikungunya Pipeline Report also highlights the unmet needs with respect to the Chikungunya.

Chikungunya Overview

Chikungunya virus (CHIKV) is an arthropod-borne alphavirus primarily transmitted by Aedes aegypti and Aedes albopictus mosquitoes, and is responsible for causing Chikungunya fever-an acute febrile illness marked by high fever, maculopapular rash, myalgia, and, most notably, severe and often incapacitating arthralgia. The name ""Chikungunya"" is derived from the Makonde language, meaning ""to become contorted,"" reflecting the stooped posture of sufferers due to joint pain. While the acute phase of the illness typically resolves within a week, a significant number of patients develop chronic, relapsing arthritis or arthralgia that can persist for months or even years, mimicking inflammatory rheumatic conditions.

Chikungunya Emerging Drugs Profile

* HydroVax-005 CHIKV: Najit Technologies, Inc.

HydroVax-005 CHIKV, developed by Najit Technologies, Inc., is an investigational inactivated vaccine candidate for the prevention of chikungunya virus (CHIKV) infection. The vaccine utilizes a novel site-directed hydrogen peroxide-based inactivation method (the HydroVax platform) that preserves key neutralizing epitopes on the virus, resulting in robust immune responses and protection in preclinical models, outperforming traditional inactivation techniques like heat or UV that can damage these epitopes. Currently, the drug is in the Phase I stage of its development for the treatment of Chikungunya.

If you're tracking ongoing Chikungunya Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Chikungunya Treatment Drugs [https://www.delveinsight.com/sample-request/chikungunya-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Chikungunya Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Chikungunya with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chikungunya Treatment.
* Chikungunya Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chikungunya Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chikungunya market.

Chikungunya Companies

Najit Technologies, Inc., Auro Vaccines, Clayton Biotechnologies Inc . and others.

Chikungunya Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Chikungunya Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Chikungunya Pipeline Report covers it all - check it out now @ Chikungunya Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/chikungunya-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chikungunya Pipeline Report

* Coverage- Global
* Chikungunya Companies- Najit Technologies, Inc., Auro Vaccines, Clayton Biotechnologies Inc . and others.
* Chikungunya Pipeline Therapies such as MV-CHIK, MMR-vaccine, VLA1553, V184 , and others.
* Chikungunya Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chikungunya Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Chikungunya Treatment landscape in this detailed analysis @ Chikungunya Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/chikungunya-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Chikungunya: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chikungunya- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* HydroVax-005 CHIKV: Najit Technologies, Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Chikungunya Key Companies
* Chikungunya Key Products
* Chikungunya- Unmet Needs
* Chikungunya- Market Drivers and Barriers
* Chikungunya- Future Perspectives and Conclusion
* Chikungunya Analyst Views
* Chikungunya Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chikungunya-pipeline-drugs-report-2025-emerging-therapies-clinical-developments-and-drug-insights-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chikungunya-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chikungunya Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight here

News-ID: 4216932 • Views:

More Releases from ABNewswire

Acute Lymphocytic Leukemia Pipeline Outlook Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Acute Lymphocytic Leukemia Pipeline Outlook Report 2025: Emerging Therapies, Cli …
DelveInsight's, "Acute Lymphocytic Leukemia Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious
Exploring the Role of Business Loans in Building Entrepreneurial Success
Exploring the Role of Business Loans in Building Entrepreneurial Success
In most cases, expanding an enterprise entails more than good ideas and labor. It requires capital to seize new opportunities, grow or to survive through difficult periods. The process of learning how to acquire the appropriate business loan to grow your business can mean the difference between achieving your objectives and stagnating. Having an appropriate funding partner will enable you to take your business to the next level in the
Diarrhea Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Diarrhea Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, …
DelveInsight's "Diarrhea Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Diarrhea pipeline landscape. It covers the Diarrhea Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diarrhea Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious about the latest updates in the Diarrhea Pipeline?
Planning the Perfect Holiday Gathering in Mineral Wells, TX for Memorable Celebrations
Planning the Perfect Holiday Gathering in Mineral Wells, TX for Memorable Celebr …
Holidays are occasions to spend with people you love as well as have an opportunity to swap stories that will be a lifetime memory. In the Mineral Wells, TX the season of celebrations gained a festivity different touch. It is available on small town, locality and home-town atmosphere which also makes it the best at celebrating memorable moments. You can have your family dinner, a basic friend get-togathering, or even

All 5 Releases


More Releases for Chikungunya

Chikungunya market is expected to reach USD 1.4 billion by 2034
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), transmitted primarily by Aedes aegypti and Aedes albopictus. The infection is characterized by sudden high fever, severe joint pain, rash, headache, and fatigue. While rarely fatal, chikungunya often leads to chronic arthritis-like symptoms lasting months to years, creating a significant burden on healthcare systems. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71953 Global spread is accelerating due to
Chikungunya Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportu …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. What Is the Projected Growth of the Chikungunya Market? In recent times, there has been robust growth in the chikungunya market size. It is projected to expand from $0.59 billion in 2024 to $0.65 billion in 2025, with a compound annual growth rate (CAGR) of 9.8%. Factors that have contributed to this
Chikungunya Pipeline Insight 2025: 10+ Advancing Therapies and Key Companies in …
The therapeutic landscape for Chikungunya, a viral disease transmitted by mosquitoes that causes severe joint pain, fever, and rash, is rapidly evolving, fueled by advancements in antiviral research and vaccine development. Leading biopharmaceutical companies such as Valneva, Moderna Therapeutics, Themis Bioscience, FIT Biotech, Bharat Biotech, and Emergex Vaccines are at the forefront of developing innovative therapies, targeting various stages of the virus lifecycle, immune modulation, and pain management to alleviate
Chikungunya Fever Global Clinical Trials Review, H2, 2018: Researchmoz.us
Researchmoz added Most up-to-date research on "Chikungunya Fever Global Clinical Trials Review, H2, 2018" to its huge collection of research reports. An insight on the important factors and trends influencing the market. Latest clinical trial report, Chikungunya Fever Global Clinical Trials Review, H2, 2018" provides an overview of Chikungunya Fever clinical trials scenario. This report provides top line data relating to the clinical trials on Chikungunya Fever. Report includes an overview
Chikungunya Fever Market Segmentation 2018 with Recent Trend by 2023
Chikungunya Fever Market - Highlights Chikungunya fever is a mosquito borne disease. The caU.S.Ative agent is a RNA virus that belongs to the alphavirus genus of the family Togaviridae. The transmission of the disease occurs from human to human by the bites of infected female mosquitoes. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. The symptoms of the disease includes muscle pain, headache, nausea, fatigue and rash. There is
Chikungunya Fever Market Worldwide Segmentation with Top Key Merchant – Avail …
Chikungunya Fever Market - Highlights Chikungunya fever is a mosquito borne disease. The caU.S.Ative agent is a RNA virus that belongs to the alphavirus genus of the family Togaviridae. The transmission of the disease occurs from human to human by the bites of infected female mosquitoes. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. The symptoms of the disease includes muscle pain, headache, nausea, fatigue and rash. There is